Quick Answer
Inmune Bio, Inc. reported Cash And Cash Equivalents At Carrying Value of $24.75 million for the year ending 2025.
- Inmune Bio, Inc. showed an increase of +18.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Inmune Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $1.96 million | Q2 2018: $1.11 million | Q3 2018: $650.9 thousand | Q1 2019: $6.05 million | Q2 2019: $9.36 million | Q3 2019: $7.38 million | Q1 2020: $5.93 million | Q2 2020: $4.82 million | Q3 2020: $24.31 million | Q1 2021: $45.34 million | Q2 2021: $39.52 million | Q3 2021: $84.47 million | Q1 2022: $66.73 million | Q2 2022: $61.21 million | Q3 2022: $57.41 million | Q1 2023: $51.00 million | Q2 2023: $47.83 million | Q3 2023: $41.81 million | Q1 2024: $26.00 million | Q2 2024: $31.07 million | Q3 2024: $33.55 million | Q1 2025: $19.34 million | Q2 2025: $33.37 million | Q3 2025: $27.73 million.
- Over the full 10 years of available data (2016 to 2025), Inmune Bio, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 17,372.2%.
- Historical annual values: Fiscal year 2025: $24.75 million | Fiscal year 2024: $20.92 million | Fiscal year 2023: $35.85 million | Fiscal year 2022: $52.15 million | Fiscal year 2021: $74.81 million | Fiscal year 2020: $21.97 million | Fiscal year 2019: $7.00 million | Fiscal year 2018: $186.2 thousand | Fiscal year 2017: $1.37 million | Fiscal year 2016: $141.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: